A patient with Stage 4 chronic kidney disease (CKD) presents with hyperkalemia and left ventricular hypertrophy. Which nursing intervention should be prioritized to address the patient's immediate health concerns while considering the progression of CKD and associated cardiovascular risks?

D) Collaborate with the healthcare provider to adjust antihypertensive medications and consider a potassium-binding agent.

A) Administer a potassium-sparing diuretic as prescribed to manage hyperkalemia.

B) Educate the patient on a low-potassium diet to help prevent further hyperkalemia.

C) Initiate dialysis immediately to resolve hyperkalemia and prevent cardiac complications.

D) Collaborate with the healthcare provider to adjust antihypertensive medications and consider a potassium-binding agent.

A patient with Stage 4 chronic kidney disease presents with hyperkalemia and an elevated serum creatinine level. Which initial nursing intervention should the nurse prioritize to address the patient's hyperkalemia?

B) Restrict foods high in potassium from the patient's diet.

A) Encourage the patient to increase fluid intake.

B) Restrict foods high in potassium from the patient's diet.

C) Administer a loop diuretic as prescribed.

D) Prepare the patient for hemodialysis immediately.

A patient with a history of chronic kidney disease presents with persistent fatigue, palpitations, and a serum potassium level of 6.1 mEq/L. Given these findings, what is the priority nursing intervention to address the patient's current condition?

A) Administer a potassium-binding agent as prescribed to lower serum potassium levels.

B) Increase the dosage of antihypertensive medication to manage elevated blood pressure.

C) Encourage the patient to increase fluid intake to promote renal function.

D) Provide dietary counseling to reduce potassium intake from food sources.

A patient with chronic kidney disease presents with hyperkalemia and an elevated blood pressure despite adherence to antihypertensive medication. Which nursing intervention is most appropriate to address the patient's hyperkalemia and prevent cardiac complications?

B) Administer a prescribed potassium-binding agent and educate the patient on dietary potassium restrictions.

A) Encourage the patient to increase their intake of potassium-rich foods to balance potassium levels.

B) Administer a prescribed potassium-binding agent and educate the patient on dietary potassium restrictions.

C) Increase the dosage of the patient's current antihypertensive medication to better control blood pressure.

D) Suggest fluid restriction to manage peripheral edema and prevent further kidney damage.

A patient with chronic kidney disease (CKD) and hyperkalemia is being treated with a potassium-binding agent and a low-dose diuretic. Despite these treatments, the patient experiences occasional dizziness, especially when standing up quickly. What is the most appropriate nursing action to address this concern?

B) Educate the patient on slow positional changes to manage orthostatic hypotension.

A) Instruct the patient to increase fluid intake to prevent dehydration.

B) Educate the patient on slow positional changes to manage orthostatic hypotension.

C) Advise the patient to completely avoid foods containing potassium.

D) Suggest the patient take an over-the-counter antihistamine to help with dizziness.

A patient with chronic kidney disease and persistent hyperkalemia has been started on a potassium-binding agent and a low-dose diuretic. She reports occasional dizziness when standing. What is the most appropriate nursing action to address her dizziness?

B) Advise her to stand up slowly from a seated or lying position.

A) Increase her fluid intake to prevent dehydration.

B) Advise her to stand up slowly from a seated or lying position.

C) Discontinue the diuretic and report to the healthcare provider.

D) Encourage the use of compression stockings to improve circulation.

A patient with chronic kidney disease has recently shown an increase in serum creatinine to 2.3 mg/dL and a decrease in eGFR to 28 mL/min/1.73 m², along with a hemoglobin drop to 10.8 g/dL. Which of the following interventions should the nurse prioritize to address the patient's anemia given the current laboratory findings?

C) Monitor for signs of iron deficiency before starting ESAs.

A) Initiate erythropoiesis-stimulating agents (ESAs) therapy immediately.

B) Administer a high-protein diet to improve kidney function and anemia.

C) Monitor for signs of iron deficiency before starting ESAs.

D) Increase the patient's fluid intake to enhance renal perfusion.

A patient with chronic kidney disease has been noted to have an increase in serum creatinine and a decrease in eGFR. The healthcare team is considering initiating erythropoiesis-stimulating agents (ESAs) for her anemia. As a nurse, what is the most appropriate intervention to implement prior to starting ESAs?

B) Assess the patient's iron levels and ensure adequate iron stores.

A) Educate the patient on the importance of maintaining a low-protein diet.

B) Assess the patient's iron levels and ensure adequate iron stores.

C) Monitor the patient's blood pressure closely for any hypertension.

D) Schedule a renal ultrasound to evaluate kidney size and structure.

A patient with chronic kidney disease (CKD) is being treated with erythropoiesis-stimulating agents (ESAs) and iron supplementation. Recent lab results show an increase in serum creatinine and a decrease in eGFR. Which nursing intervention is most appropriate to address the patient's current clinical status?

B) Monitor blood pressure closely and collaborate with healthcare provider to adjust antihypertensive medications.

A) Increase dietary protein to promote muscle strength and energy.

B) Monitor blood pressure closely and collaborate with healthcare provider to adjust antihypertensive medications.

C) Encourage the patient to continue all current medications without changes.

D) Suggest the patient stop all medications temporarily to reassess the need.

A patient with chronic kidney disease (CKD) is being treated with erythropoiesis-stimulating agents (ESAs) and reports improved energy levels, but her serum creatinine has increased and eGFR has decreased. Which nursing intervention is most appropriate to address her current condition and support renal function?

B) Monitor blood pressure closely and notify the healthcare provider of any significant changes.

A) Encourage a high-protein diet to increase muscle mass and energy.

B) Monitor blood pressure closely and notify the healthcare provider of any significant changes.

C) Increase fluid intake to enhance renal perfusion and excretion.

D) Advise the patient to take over-the-counter diuretics to reduce fluid retention.

chronic kidney disease - Nursing Case Study

Pathophysiology

• Primary mechanism: Chronic kidney disease (CKD) primarily results from prolonged injury or stress to the nephrons, often due to diabetes or hypertension. This leads to glomerular damage and reduced filtration capacity, progressively impairing the kidneys' ability to filter waste and excess fluid from the blood.

• Secondary mechanism: As nephrons are lost, the remaining nephrons undergo hyperfiltration to compensate, which increases intraglomerular pressure. Over time, this adaptation leads to further nephron damage, promoting a cycle of progressive renal function decline.

• Key complication: The accumulation of toxins and fluid due to impaired filtration can cause systemic complications, including cardiovascular disease and electrolyte imbalances, which are significant contributors to morbidity and mortality in CKD patients.

Patient Profile

Demographics:

54 years old, female, office manager

History:

• Key past medical history: Hypertension, Type 2 Diabetes, Chronic Kidney Disease Stage 3

• Current medications: Lisinopril, Metformin, Amlodipine, Atorvastatin

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increased fatigue and swelling in the lower extremities

• Key symptoms: Persistent fatigue, peripheral edema, mild shortness of breath, occasional headaches

• Vital signs: Blood pressure 150/95 mmHg, heart rate 88 bpm, respiratory rate 18 breaths per minute, temperature 98.6°F

Section 1

New Diagnostic Results:

Following the initial presentation, the patient underwent a series of diagnostic tests to further evaluate her worsening symptoms and to assess the progression of her chronic kidney disease. The laboratory results revealed a serum creatinine level of 2.1 mg/dL, indicating a decline in renal function compared to her previous baseline of 1.8 mg/dL. Her estimated glomerular filtration rate (eGFR) was calculated to be 35 mL/min/1.73 m², confirming the advancement to Stage 4 CKD. Additionally, her blood urea nitrogen (BUN) was elevated at 48 mg/dL, and a significant electrolyte imbalance was noted with hyperkalemia, as her serum potassium was measured at 5.8 mEq/L.

In conjunction with these findings, urine analysis showed moderate proteinuria and the presence of red blood cell casts, suggesting ongoing nephron damage and inflammation. The patient's lipid profile also indicated dyslipidemia, with elevated LDL cholesterol at 140 mg/dL despite being on atorvastatin, which may contribute to her cardiovascular risk. An echocardiogram was performed to assess her mild shortness of breath and revealed left ventricular hypertrophy, a common cardiac complication linked to hypertension and CKD.

These diagnostic results highlight the need for an adjustment in her treatment plan, particularly addressing her hyperkalemia and optimizing her blood pressure and glucose control to slow further renal deterioration. This situation requires careful clinical reasoning to balance the management of her CKD with the prevention of cardiovascular events, necessitating a multidisciplinary approach. The healthcare team must consider potential medication adjustments, such as reviewing her current antihypertensive regimen and exploring options for potassium-binding agents, while also emphasizing lifestyle modifications to support her overall health.

Section 2

Change in Patient Status:

Two weeks following the adjustment of her treatment plan, the patient returned for a follow-up appointment. She reported persistent fatigue and occasional palpitations, which raised concerns about her cardiovascular stability and electrolyte disturbances. A physical examination revealed mild peripheral edema and a slightly elevated blood pressure of 148/92 mmHg, despite adherence to her prescribed antihypertensive medications. Her heart rate was regular at 92 beats per minute, though slightly elevated, which corresponded with her subjective experience of palpitations.

Laboratory tests were repeated to monitor her renal function and electrolyte levels. The results showed a worsening of hyperkalemia, with a serum potassium level now at 6.1 mEq/L, necessitating immediate intervention to prevent cardiac complications. Her serum creatinine had increased further to 2.4 mg/dL, and the eGFR had declined to 30 mL/min/1.73 m², indicating a continued progression of her kidney disease. Additionally, her BUN had risen to 52 mg/dL, and the proteinuria remained significant, emphasizing the ongoing nephron damage.

These findings required prompt clinical reasoning to adjust her management plan once more. The healthcare team decided to initiate treatment with a potassium-binding agent and explore potential modifications to her antihypertensive therapy to better control her blood pressure and reduce cardiac strain. Further, they planned to investigate potential secondary causes of her worsening renal function, such as medication side effects or dietary factors contributing to hyperkalemia. This change in patient status underscored the need for close monitoring and a comprehensive approach to managing her complex condition, integrating nephrology and cardiology perspectives to optimize her care.

Section 3

Response to Interventions:

Following the initiation of treatment with a potassium-binding agent, the patient's serum potassium level showed a modest decrease to 5.7 mEq/L, which was a positive step in managing the hyperkalemia but still required further intervention to ensure safety. The healthcare team decided to maintain a close watch on her electrolyte levels and reinforce dietary counseling to limit potassium intake, emphasizing the need to avoid high-potassium foods. Despite these adjustments, the patient's blood pressure remained elevated at 150/94 mmHg during subsequent visits, prompting the team to consider additional antihypertensive strategies. They decided to introduce a low-dose diuretic to help manage both blood pressure and peripheral edema, with careful monitoring for any signs of electrolyte imbalance.

The patient reported a slight reduction in her fatigue and palpitations, suggesting some improvement, yet she continued to experience occasional episodes of dizziness, particularly when standing up quickly. This raised concerns about orthostatic hypotension as a possible side effect of the new diuretic, necessitating a careful reassessment of her medication regimen. To address this, the team advised her on positional changes and scheduled a follow-up to evaluate her blood pressure readings in different positions. Meanwhile, the slight decrease in heart rate to 88 beats per minute was observed, indicating a potential stabilization of her cardiovascular status, albeit requiring ongoing surveillance.

These interventions highlighted the complexity of managing her chronic kidney disease and its associated complications, emphasizing the importance of a tailored and dynamic approach. The healthcare team remained vigilant in their monitoring efforts, prepared to make further adjustments as needed based on the patient's evolving response. The focus was not only on immediate symptom management but also on preventing further deterioration of her renal function, ensuring a comprehensive approach that would guide the next steps in her treatment journey.

Section 4

New Diagnostic Results:

During the follow-up visit, the healthcare team decided to conduct a comprehensive diagnostic work-up to further evaluate the patient's condition and adjust the treatment plan accordingly. A repeat set of laboratory tests revealed a concerning trend: her serum creatinine level had increased to 2.3 mg/dL from a previous level of 2.0 mg/dL, indicating a potential progression of her chronic kidney disease. Additionally, her estimated glomerular filtration rate (eGFR) had decreased to 28 mL/min/1.73 m², confirming a decline in renal function. The patient's hemoglobin level was also noted to have dropped to 10.8 g/dL, suggesting the development of anemia, a common complication associated with chronic kidney disease.

These findings prompted the healthcare team to consider the implications of worsening renal function and anemia on her overall health status. They recognized the need to address the anemia promptly, as it could contribute to her fatigue and exacerbate her cardiovascular issues. The team discussed the possibility of initiating erythropoiesis-stimulating agents (ESAs) to manage her anemia, along with iron supplementation if iron deficiency was confirmed. They also contemplated adjusting her antihypertensive regimen to better protect her renal function, considering the intricate balance between managing blood pressure and avoiding further renal impairment.

The new diagnostic results underscored the need for a multifaceted approach, integrating renal protection strategies, anemia management, and continued cardiovascular monitoring. The healthcare team planned to closely monitor the patient's response to these interventions through regular follow-ups and laboratory assessments, remaining vigilant for any signs of further complications. This proactive stance aimed to stabilize her condition and improve her quality of life, while also preparing for potential future challenges in the management of her chronic kidney disease.

Section 5

Change in Patient Status:

Several weeks after the initiation of erythropoiesis-stimulating agents (ESAs) and iron supplementation, the patient returned for a follow-up appointment. During the assessment, she reported a slight improvement in her energy levels, but still experienced persistent fatigue. New laboratory results showed a modest increase in her hemoglobin level to 11.5 g/dL, indicating a positive response to the anemia treatment. However, her serum creatinine had risen further to 2.5 mg/dL, and her eGFR had decreased to 25 mL/min/1.73 m², suggesting a continued decline in renal function. Her blood pressure was recorded at 145/90 mmHg, slightly elevated despite adherence to her antihypertensive regimen.

The healthcare team recognized the need to reassess her treatment plan, given the mixed response to current interventions. They deliberated over potential adjustments to her antihypertensive medications, focusing on options that would provide better renal protection while managing her blood pressure more effectively. The team also emphasized the importance of dietary modifications, including sodium restriction and adequate hydration, to support her renal function and overall health.

In light of the ongoing progression of her chronic kidney disease, the team discussed the possibility of preparing for renal replacement therapy, should her condition continue to deteriorate. They planned to educate the patient and her family about the different modalities, such as dialysis and kidney transplantation, to ensure informed decision-making. The team remained committed to closely monitoring her clinical status, with frequent follow-ups and laboratory assessments, aiming to mitigate complications and optimize her quality of life as she navigates the challenges of her condition.